Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M, Bajetta E, Zilembo N, de Braud F, Di Leo A, Verusio C, D'Aprile M, Scanni A, Barduagni M, Barduagni A [corrected to Barduagni M], et al. Di Bartolomeo M, et al. Among authors: bajetta e. Acta Oncol. 1993;32(2):235-8. doi: 10.3109/02841869309083918. Acta Oncol. 1993. PMID: 7686766 Clinical Trial.
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N. Sertoli MR, et al. Among authors: bajetta e. Melanoma Res. 1999 Oct;9(5):503-9. doi: 10.1097/00008390-199910000-00010. Melanoma Res. 1999. PMID: 10596917 Clinical Trial.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N. Bajetta E, et al. Ann Oncol. 2006 Apr;17(4):571-7. doi: 10.1093/annonc/mdl007. Epub 2006 Feb 9. Ann Oncol. 2006. PMID: 16469753 Free article. Clinical Trial.
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E, Negretti E, Giannotti B, Brogelli L, Brunetti I, Sertoli MR, Bernengo MG, Sofra MC, Maifredi G, Zumiani G, et al. Bajetta E, et al. Am J Clin Oncol. 1990 Oct;13(5):405-9. doi: 10.1097/00000421-199010000-00008. Am J Clin Oncol. 1990. PMID: 2220660 Clinical Trial.
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L, et al. Bajetta E, et al. Cancer. 1993 Nov 15;72(10):3099-105. doi: 10.1002/1097-0142(19931115)72:10<3099::aid-cncr2820721035>3.0.co;2-4. Cancer. 1993. PMID: 7693327 Clinical Trial.
354 results